Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
INCLUSION CRITERIA~* Histologically-confirmed adenocarcinoma of the rectum. Clinical stages T3; T4; or N1 as determined by endoscopic ultrasound; or a rectal CT or MRI scan are eligible, including T3 N0; T3 N1; T4 N0; T4 N1; T1-4 N1. Rectal cancers are defined as those whose distal border extends to within 12 cm of the anal verge.~* Age ≥ 18~* Karnofsky performance status (KPS) ≥ 70~* Leukocyte count \> 3,500 x 10e6/µL~* Platelet count \> 100,000/µL~* Serum glutamic-oxaloacetic transaminase (SGOT) \< 2.5 x institutional upper limits of normal (ULN)~* Serum glutamic-pyruvic transaminase (SGPT) \< 2.5 x ULN~* Alkaline phosphatase \< 2.5 x ULN~* Total bilirubin \< 1.5x ULN~* Creatinine:~  * Within normal institutional limits~ * OR~ * Creatinine clearance \> 60 mL/min/1.73 m2 (if serum creatinine levels above institutional normal)~* Ability to swallow pills without difficulty~* Women of child-bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG), within 72 hours prior to the start of study medication~* Women of child-bearing potential must be using an adequate method of contraception to avoid pregnancy throughout the treatment~EXCLUSION CRITERIA~* Metastatic (M1) or stage IV disease~* Prior history of treatment with cetuximab or other therapy targeting EGFR~* Prior history of anti-cancer murine monoclonal antibody therapy~* Prior pelvic or whole abdominal radiotherapy~* Uncontrolled intercurrent illness including, but not limited to:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Psychiatric illness / social situations that would limit compliance with study requirements~* Patients with a concurrent malignancy or previous malignancy within 5 years of screening will be excluded from this study (EXCEPTION: concurrent or previous non-melanoma skin cancer, hematolymphoid malignancy or carcinoma in-situ of the cervix may be allowed at the investigator's discretion)~* Inability to sign written consent~* Pregnant or breastfeeding~* Unwilling or unable to use effective contraception in self or partner for the entire study period and for up to 4 weeks after the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 - Cetuximab + Capecitabine-800 + XRT + Oxaliplatin-100 (Type: EXPERIMENTAL): * Cetuximab 250 mg/m² / week~* Capecitabine 800 mg/m²~* Radiotherapy (XRT)~* Oxaliplatin 100 mg/m², Days 2 and 23
- Group 2 - Cetuximab + Capecitabine-700 + XRT + Oxaliplatin-85 (Type: EXPERIMENTAL): * Cetuximab 250 mg/m² / week~* Capecitabine 700 mg/m²~* Radiotherapy (XRT)~* Oxaliplatin 85 mg/m², Days 2 and 23
- Group A - Cetuximab + Capecitabine-800 + XRT (Type: EXPERIMENTAL): * Cetuximab 250 mg/m² / week~* Capecitabine 800 mg/m²~* Radiotherapy (XRT)
- Group B - Cetuximab + Capecitabine-1000 + XRT (Type: EXPERIMENTAL): * Cetuximab 250 mg/m² / week~* Capecitabine 1000 mg/m²~* Radiotherapy (XRT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy